Collaborators at the University of Washington aim here to examine CSP-specific memory B cells induced by RTS,S/AS01 vaccination in subjects who participated in an earlier controlled human malaria infection study at the Walter Reed Army Institute of Research. These persistent B cells and the antibodies they produce will be identified and characterized in select subjects that were protected from a second controlled human malaria infection and did not receive a booster dose. This research, undertaken in part with Seattle Children’s Hospital, aims to understand the role memory B cells may have in maintaining protective RTS,S-induced antibody responses. GSK is also a partner in this work.

Related resources:

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, et al.
Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: phase 2a controlled human malaria infection and immunogenicity study.
The Journal of Infectious Diseases. 2016; 214(5).